Allergy is an IgE antibody-mediated hypersensitivity disorder and is a common disease. Recognition of allergens by specific IgE antibodies produced after sensitization is a key cause of allergic inflammation and may result in a variety of allergic symptoms, including food allergy, asthma and skin inflammation. While drug-based anti-inflammatory therapy can reduce allergy symptoms, only allergen-specific immunotherapy is the fundamental treatment for the cause. Creative BioMart can provide pMHC-based allergy therapy development services to restore immune homeostasis in allergic individuals through relevant pMHC-coated NPs as a viable alternative to allergy treatment.

pMHC-NPs Therapy for Allergic Disorders

Allergic disease is an important and expanding health problem worldwide, a systemic immune disease triggered by adaptive immune responses to common allergens, regardless of the organ affected, characterized by the presence of allergen specific IgE antibodies and eosinophilic inflammation. Allergen avoidance and drug therapy cannot control the disease at its root, only allergy immunotherapy has the potential to ameliorate the disease by affecting the underlying immune mechanisms and inducing immune tolerance.

Fig.1 Allergy is a systemic immune disease.( Jørgen N L, et al., 2016)

Based on immunotherapy strategies, related pMHC-like coated NPs may become a viable option for allergy treatment approaches. Antigen-specific pMHC complexes trigger the induction and expansion of homologous self-regulatory Allergen-specific CD4⁺CD25⁺ regulatory T cells that produce IL-10 and TGF-β and have the ability to inhibit local Th2 cell responses and redirect antibody class conversion to IgG and IgA, thus failing to trigger an allergic response. Coating of pMHC complexes on nanoparticles increases targeted therapy and protection from degradation.

Our Services

• pMHC-NP Engineering Design. We design key pMHC-NP engineering to guide the development of next-generation agents suitable for allergy drug development and clinical translation. This includes screening of allergy-specific antigenic peptides, selection of MHC molecules, preparation of pMHC complexes, and pMHC-NP design such as material, density, and activity.
• Pharmacodynamic activity and bioavailability determination. We perform in vivo experiments through animal allergy models, collect biological samples of tissues, organs, and body fluids to quantify pMHC-NP to determine in vivo bioavailability, as well as perform pharmacokinetic characterization and analysis of drug distribution and therapeutic specificity.

Featured Technologies

• Cellular expression technology. Solve pMHC yield and purity limitations by cellular expression of recombinant pMHC complexes and by using chromatography and mass spectrometry.
• Nanoparticle construction technology. Construction of nanoparticles with unique physical and chemical properties, increased pMHC targeting and protection and for labeling analysis.
• Mouse model technology. Continuous refinement of disease models further facilitates preclinical evaluation of pMHC-NP drug candidates.

The expansion of antigen-specific regulatory T cells is a potential approach for the treatment of autoimmune diseases, and nanotechnology offers new opportunities for the induction of regulatory T cells by pMHC in vivo. Creative BioMart can help our customers to realize the development of pMHC-NP for allergy treatment, and you can contact us for more details.

Reference

• Jørgen N L, et al. "Allergy immunotherapy: the future of allergy treatment." Drug Discovery Today (2016),12(1):26-37.